SPATA2L

Across TCGA pan-cancer cohorts, SPATA2L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA2L data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SPATA2L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA2L expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, LUAD, and HNSC are the cancer types where SPATA2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.607	0.925	.001	44	view →
LUAD	OS	Median	All	0.892	0.624	.005	22	view →
HNSC	OS	Median	All	0.564	0.940	.010	20	view →
PDAC	OS	Median	II,III,IV	0.648	0.946	.002	10	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA2L–LSCC (DFS)

Open the LSCC breakdown →